Study register · detail Kohortenstudie · Endometriosis · 2026

Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry.

Ahmed et al. ·The Australian & New Zealand journal of obstetrics & gynaecology

No direction reported GRADE Low

Samplen = 101 Pat.

DesignKohortenstudie

Summary

n=101 Patientinnen mit Endometriose-assoziiertem Schmerz, CBMP-Therapie über 24 Monate; Verbesserung von BPI Severity, BPI Interference, SF-MPQ-2, Schmerz-VAS, EQ-5D-5L, GAD-7 und SQS zu allen Follow-ups (p<0.001). Mittlere verschriebene OME sank von 19.9±17.2 auf 14.8±15.9 mg/Tag. Nebenwirkungen bei 17.8% (18 Patientinnen; 165 AEs, 50.9% mild), am häufigsten Fatigue (15.8%).

Confidence in the evidence

Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile

Sample size ★★★★★

Blinding —

Effect size —

Citations / year —

Authors

Ahmed T, Erridge S, Clarke E, McLachlan K, Coomber R, Barnes S, Medniuk AD, Guru R, Holden W, Sajad M

DOI 10.1111/ajo.70173↗

Design: Kohortenstudie

Abstract

Background: Endometriosis affects up to 10% of biological females of reproductive age. Current treatment options are limited and often unsuitable for prolonged use. Cannabis-based medicinal products (CBMPs) have emerged as an alternative for pain management. Aims: To analyse changes in patient-reported outcome measures (PrOMs), prescribed opioid burden, and the prevalence of adverse events (AEs) in patients prescribed CBMPs for endometriosis-associated pain. Materials And Methods: This was an observational analysis of prospectively collected data from the UK Medical Cannabis Registry. Biological females (>/= 18 years) with a primary diagnosis of endometriosis, enrolled >/= 2 years prior to data extraction on 06/01/2025, were included. PrOMs and prescribed oral morphine equivalents (OME) were assessed between baseline and 1, 3, 6, 12, 18, and 24 months. Changes from baseline were assessed by repeated-measures ANOVA and Bonferroni-adjusted post hoc pairwise t-tests. p < 0.050 was considered statistically significant. Results: One hundred and one patients were included. Improvements from baseline were observed in BPI Severity, BPI Interference, SF-MPQ-2 Total, Pain VAS, EQ-5D-5L Index, GAD-7, and SQS at all follow-ups (p < 0.001). Mean prescribed OME decreased from 19.9 +/- 17.2 mg/day at baseline to 14.8 +/- 15.9 mg/day at 24 months. Eighteen participants (17.8%) reported 165 AEs, of which 84 (50.9%) were mild. The most frequent were fatigue (n = 16; 15.8%), lethargy (n = 15; 14.9%), and headache (n = 13; 12.9%). Conclusion: CBMP treatment was associated with sustained improvements in pain, health-related quality of life, sleep, and anxiety at 24 months, with a favourable AE profile. Randomised controlled trials are required to establish efficacy and safety.

The impediment to action advances action. — Marcus Aurelius